Niklas Bruse

Niklas Bruse

Auto-generated profile, based on publicly available information

Niklas Bruse

Radboud university medical center, Radboud Institute for Molecular Life Sciences, Department of Intensive Care Medicine, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, the Netherlands; Radboud Center for Infectious Diseases (RCI), Radboud university medical center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, the Netherlands

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2021 in Critical Care
Verified
Journal Article
Open access
PDF file
EKEmma J. Kooistra
Emma J. Kooistra
MBMiranda van Berkel
Miranda van Berkel
NKNoortje F. van Kempen
Noortje F. van Kempen
CLCeline R. M. van Latum
Celine R. M. van Latum
NBNiklas Bruse
Niklas Bruse
PPPeter Pickkers
Peter Pickkers
Background: Procalcitonin (PCT) and C-reactive protein (CRP) were previously shown to have value for the detection of secondary infections in critically ill COVID-19 patients. However, since the introduction of immunomodulatory therapy, the value of these biomarkers is unclear. We investigated PCT and CRP kinetics in critically ill COVID-19 patients treated with dexamethasone with or without tocilizumab, and assessed the value of these biomarkers to detect secondary bacterial infections.Methods: In this prospective study, 190 critically ill COVID-19 patients were divided into three treatment groups:no dexamethasone, no tocilizumab (D−T−),dexamethasone, no tocilizumab (D+T−), anddexamethasone and tocilizumab (D+T+). Serial data of PCT and CRP were aligned on the last day of dexamethasone treatment, and kinetics of these biomarkers were analyzed between 6 days prior to cessation of dexamethasone and 10 days afterwards. Furthermore, the D+T− and D+T+ groups were subdivided into secondary infection and no-secondary infection groups to analyze differences in PCT and CRP kinetics and calculate detection accuracy of these biomarkers for the occurrence of a secondary infection.Results: Following cessation of dexamethasone, there was a rebound in PCT and CRP levels, most pronounced in the D+T− group. Upon occurrence of a secondary infection, no significant increase in PCT and CRP levels was observed in the D+T− group (p = 0.052 andp = 0.08, respectively). Although PCT levels increased significantly in patients of the D+T+ group who developed a secondary infection (p = 0.0003), this rise was only apparent from day 2 post-infection onwards. CRP levels remained suppressed in the D+T+ group. Receiver operating curve analysis of PCT and CRP levels yielded area under the curves of 0.52 and 0.55, respectively, which are both markedly lower than those found in the group of COVID-19 patients not treated with immunomodulatory drugs (0.80 and 0.76, respectively, withpvalues for differences between groups of 0.001 and 0.02, respectively).Conclusions: Cessation of dexamethasone in critically ill COVID-19 patients results in a rebound increase in PCT and CRP levels unrelated to the occurrence of secondary bacterial infections. Furthermore, immunomodulatory treatment with dexamethasone and tocilizumabconsiderably reducesthe value of PCT and CRP for detection of secondary infections in COVID-19 patients.

8 August 2022 in Journal of Innate Immunity
Verified
Journal Article
Open access
PDF file
AJAron Jansen
Aron Jansen
NBNiklas Bruse
Niklas Bruse
NWNicole Waalders
Nicole Waalders
JGJelle Gerretsen
Jelle Gerretsen
DRDaniëlle Rijbroek
Daniëlle Rijbroek
MKMatthijs Kox
Matthijs Kox
Cytokine production by ex vivo (EV)-stimulated leukocytes is commonly used to gauge immune function and frequently proposed to guide immunomodulatory therapy. However, whether EV cytokine production capacity accurately reflects the in vivo (IV) immune status is largely unknown. We investigated relationships between EV monocyte cytokine responses and IV cytokine responses in a large cohort of healthy volunteers using a highly standardized IV model of short-lived LPS-induced systemic inflammation, which captures hallmarks of both hyperinflammation and immunological tolerance. Therefore, 110 healthy volunteers were intravenously challenged with 1 ng/kg LPS twice: on day 0 to determine the extent of the IV (hyper)inflammatory response and on day 7 to determine the degree of IV endotoxin tolerance. Baseline EV monocyte cytokine production capacity was assessed prior to LPS administration. Short-term and long-term EV tolerance was assessed in monocytes isolated 4 h and 7 days after LPS administration, respectively. No robust correlations were observed between baseline EV cytokine production capacity and IV cytokine responses following LPS administration. However, highly robust inverse correlations were observed between IV cytokine responses and EV cytokine responses of monocytes isolated 4 h after IV LPS administration. No correlations between IV and EV tolerance were found. In conclusion, attenuated EV cytokine production capacity reflects ongoing IV inflammation rather than immune suppression. Results of EV assays should be interpreted with caution at the risk of improper use of immuno­stimulatory drugs.

8 July 2020 in medRxiv
Verified
Preprint
Open access
PDF file
AAAnna C. Aschenbrenner
Anna C. Aschenbrenner
MMMaria Mouktaroudi
Maria Mouktaroudi
BKBenjamin Kraemer
Benjamin Kraemer
NANikolaos Antonakos
Nikolaos Antonakos
MOMarie Oestreich
Marie Oestreich
G(German COVID-19 Omics Initiative (DeCOI)
German COVID-19 Omics Initiative (DeCOI)
SUMMARY: The SARS-CoV-2 pandemic is currently leading to increasing numbers of COVID-19 patients all over the world. Clinical presentations range from asymptomatic, mild respiratory tract infection, to severe cases with acute respiratory distress syndrome, respiratory failure, and death. Reports on a dysregulated immune system in the severe cases calls for a better characterization and understanding of the changes in the immune system. Here, we profiled whole blood transcriptomes of 39 COVID-19 patients and 10 control donors enabling a data-driven stratification based on molecular phenotype. Neutrophil activation-associated signatures were prominently enriched in severe patient groups, which was corroborated in whole blood transcriptomes from an independent second cohort of 30 as well as in granulocyte samples from a third cohort of 11 COVID-19 patients. Comparison of COVID-19 blood transcriptomes with those of a collection of over 2,800 samples derived from 11 different viral infections, inflammatory diseases and independent control samples revealed highly specific transcriptome signatures for COVID-19. Further, stratified transcriptomes predicted patient subgroup-specific drug candidates targeting the dysregulated systemic immune response of the host.

20 June 2023 in Microbes and Infection
Verified
Journal Article
Open access
NBNiklas Bruse
Niklas Bruse
AJAron Jansen
Aron Jansen
JGJelle Gerretsen
Jelle Gerretsen
DRDanielle Rijbroek
Danielle Rijbroek
KWKiedo Wienholts
Kiedo Wienholts
MKMatthijs Kox
Matthijs Kox
It is largely unknown whether the gut microbiome regulates immune responses in humans. We determined relationships between the microbiota composition and immunological phenotypes in 108 healthy volunteers, using 16S sequencing, an ex vivo monocyte challenge model, and an in vivo challenge model of systemic inflammation induced by lipopolysaccharide (LPS). Significant associations were observed between the microbiota composition and ex vivo monocytic cytokine responses induced by several stimuli, most notably IL-10 production induced by Pam3Cys, P. aeruginosa and C. albicans, although the explained variance was rather low (0.3 to 4.8%). Furthermore, a number of pairwise correlations between Blautia, Bacteroides and Prevotella genera and cytokine production induced by these stimuli were identified. LPS administration induced a profound transient in vivo inflammatory response. A second LPS challenge one week after the first resulted in a severely blunted response, reflecting endotoxin tolerance. However, no significant relationships between microbiota composition and in vivo parameters of inflammation or tolerance were found (explained variance ranging from 0.4 to 1.5%, ns). The gut microbiota composition explains a limited degree of variance in ex vivo monocytic cytokine responses to several pathogenic stimuli, but no relationships with the LPS-induced in vivo immune response or tolerance was observed.

15 April 2024 in Trends in Anaesthesia and Critical Care
Verified
Journal Article
Open access
RBRemi Beunders
Remi Beunders
TSTycho M. Stegeman
Tycho M. Stegeman
NBNiklas Bruse
Niklas Bruse
SVSjef van der Velde
Sjef van der Velde
PPPeter Pickkers
Peter Pickkers